Chronic myelogenous leukemia

Chronic myelogenous leukemia

Bone marrow is the soft tissue inside bones that helps form blood cells. The bone marrow contains stem cells which eventually mature to form red and white blood cells and platelets. In leukemia, these blood cells do not mature, reproduce quickly and do not die when their normal lifespan is over. This leads to over-crowding of leukemic cells in the bone-marrow which later spill into the bloodstream. Leukemia can be acute or chronic and myeloid or lymphocytic. Chronic myelogenous leukemia is cancer that grows from cells that produce white blood cells (apart from lymphocytes) inside the bone marrow.

Causative and risk factors

Chronic myelogenous leukemia is usually associated with a chromosome abnormality called the Philadelphia chromosome. Risk factors include advancing age, male gender and exposure to ionizing radiation and electromagnetic fields.

 

Clinical presentation 

Easy bleeding tendency is observed in patients with chronic myelogenous leukemia. Other symptoms of CML include fever, fatigue, night sweats and bone pains. Anorexia (loss of appetite) and cachexia (loss of weight) are seen. The patient gets easily satiated even with little food. Pain in abdomen may be noted on left side below ribs. The skin of the patient looks pale. The spleen may become enlarged. There is an increased tendency to catch infections.

Chronic myelogenous leukemia must be differentiated from other types of leukemia such as chronic neutrophilic leukemia, acute myeloid leukemia and chronic myelomonocytic leukemia.

 

Diagnosis & Investigations

Diagnosis is based upon your symptoms, physical examination and investigations. Investigations include:

  • CBC with white blood cell differential
  • Bone marrow aspiration and biopsy

Testing for the presence of the Philadelphia chromosome

 

Treatment  

The treatment of CML includes medications, chemotherapy, and stem cell transplant.

The outlook is fairly good. The treatment does not aim to cure but to keep the disease symptoms at bay. The outcome of patient with chronic myelogenous leukemia has improved after the introduction of the drug imatinib.

Leave a Reply

Your email address will not be published. Required fields are marked *

GO FURTHER

The Best Of Health, wellness & Fitness Delivered To Your Inbox

Sign up for our newsletter to get the latest product updates, information & exclusive offers